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Abstract
Colorectal cancer is one of the leading causes of cancer-related death worldwide. Previous studies have shown that
miR-92a has an oncogenic function in several cancers and that its up-regulation is correlated with malignant clinico-
pathologic behaviors of colorectal cancer. It also has been suggested that circulating miR-92a in patients’ plasma can
be a potential biomarker for colorectal cancer. However, the precise roles of intracellular and extracellular miR-92a
are not yet understood. In this study, we examined the expression levels of miR-92a in colorectal tumors (38 cancer
specimens and 56 adenoma specimens) and paired adjacent nontumorous tissues. Increased expression of miR-92a
was frequently observed in the cancers compared with that in the adenomas and was correlated with advanced
clinical stages, tumor depth, and size. We also demonstrated that the levels of miR-92a within microvesicles (MVs)
in the plasma of mice bearing colon cancer xenografts were significantly increased compared with those in control
mice. One of the roles of intracellular and extracellular miR-92a was shown to be down-regulation of Dickkopf-3
(Dkk-3), a presumed tumor suppressor gene. Within the colon cancer cells, suppression of Dkk-3 by miR-92a con-
tributed to the cell proliferation. Extracellular miR-92a packedwithinMVs secreted by colon cancer cells was delivered
into endothelial cells and contributed to the proliferation and motility of these cells through down-regulation of the
same target gene, Dkk-3. These data suggest that intracellular and extracellular miR-92a had important roles in tumor
growth and the tumor microenvironment in colorectal cancer.
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Introduction
Colorectal cancer is one of the leading causes of cancer-related death,
causing more than 600,000 deaths per year all over the world. In
spite of early screening and the development of new chemotherapeutic
strategies, the survival rate of colorectal cancer has not been essentially
improved in the past 20 years. Thus, novel biomarkers more reliable
for the early diagnosis and early treatment to improve the survival rate
are urgently needed.
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MicroRNAs (miRNAs) are single-stranded noncoding small
RNAs that repress translation or induce degradation of target mRNAs
through binding to specific complementary sites within the 3′ un-
translated region (3′UTR) of mRNAs [1,2]. A growing body of evidence
indicates that miRNAs play crucial roles in almost all biologic processes
including proliferation, differentiation, cell survival, and cell death [3].
It has been also elucidated that dysregulation of miRNA expression con-
tributes to various human diseases, including cancer [4]. Up-regulation
and down-regulation of specific miRNAs have been described across
different cancer types, and they are known as important regulators of
oncogenes and tumor suppressor genes [5,6].
Although the majority of miRNAs exist within cells, a number of
miRNAs have been found in extracellular body fluids including serum,
plasma, saliva, urine, and other body fluids [7]. Circulating miRNAs
packed within membranous vesicular structures named shedding
microvesicles or microvesicles (MVs) are highly stable and resistant to
RNase activity [8]. MVs are 100- to 1000-nm membranous vesicular
carriers released by various kinds of cell surfaces; especially, cancer cells
are known to secrete large amounts of MVs containing various genetic
information into their surroundings, and MVs are now considered to be
an important cell-to-cell communication tool [9,10]. Furthermore, it has
been shown that the profiles of genetic products packed within MVs are
tightly correlated with various characteristics of cancer [11–13]. Thus,
there is a potential for circulating miRNAs carried by MVs (miRNAs/
MVs) to be novel noninvasive cancer biomarkers for screening, diagnosis,
and monitoring [10,14,15]. However, the precise role of circulating
miR-92a/MVs in colorectal cancer patients is not yet fully understood.
In this study, we quantified the circulating miR-92a/MVs in the
plasma of mice bearing colon cancer xenografts and confirmed a sig-
nificant increase in the miR-92a level in their plasma. We also quan-
tified the miR-92a expression in colorectal tumor tissues and adjacent
normal mucosa and examined the association between miR-92a
expression and clinicopathologic findings to determine the clinical sig-
nificance of miR-92a expression in colorectal tumors. We further ex-
amined the role of intracellular and extracellular miR-92a, and our
data implied that miR-92a secreted by colon cancer cells through MVs
could contribute to the establishment of a tumor microenvironment
promoting angiogenesis, as indicated by increased cell growth, motil-
ity, and tube formation of human umbilical vein endothelial cells
(HUVECs), through the targeting of Dickkopf-3 (Dkk-3).
Materials and Methods
Patients and Samples
All human samples were obtained from patients who had undergone
biopsy for diagnosis or surgery for resection at Fujita Health University
Hospital (Toyoake, Aichi, Japan), Osaka Medical College Hospital
(Takatsuki, Osaka, Japan), Kyouritsu General Hospital (Nagoya, Aichi,
Japan), or Saiseikai Ibaraki Hospital (Ibaraki, Osaka, Japan). Informed
consent in writing was obtained from each patient. Collection and
distribution of the samples were approved by each of the appropriate
institutional review boards. Thirty-eight patients with previously
untreated (or recently diagnosed) colorectal cancer and 56 with adeno-
mas were selected. The cancer study group consisted of 13 women
and 25 men with a median age of 70 years (range, 38-88), and the
adenoma group consisted of 25 women and 31 men with a median age
of 59 years (range, 21-75). The distribution according to other clinical
parameters is shown in Tables 1 (cancer and adenoma), 2 (cancer), and
3 (adenoma). Under a pathologist’s supervision, all tissue sample
pairs were collected from surgically or endoscopically resected tissues,
with these paired samples being from the primary tumor and its adja-
cent nontumor mucosal tissue in the same patient. All samples were
immediately stored in liquid nitrogen until RNA isolation could be
performed. Samples were homogenized by use of a spatula under
sterile conditions before total RNA isolation. Total RNAs of human
normal tissues (Human Total RNA Master Panel II) were purchased
from Clontech (Mountain View, CA).
Cell Culture and Cell Viability
All human colon cancer cell lines, DLD-1, WiDr, COLO201, and
SW480, used in this study were cultured in RPMI-1640 medium
supplemented with 10% (vol/vol) heat-inactivated FBS (Sigma-Aldrich
Co, St Louis, MO) and 2 mM L-glutamine under an atmosphere
of 95% air and 5% CO2 at 37°C. Low-passage HUVECs were
seeded in six-well plates precoated with gelatin (BIOCOAT; Becton
Table 1. Characteristics of Study Population and Expression of miR-92a in Colorectal Tumors.
Colorectal Tumors n Expression of miR-92a↑ [Case (%)]
Sex
Male 56 23 (41.1)
Female 38 10 (26.3)
Tumor
Cancer 38 25 (65.8)*
Adenoma 56 8 (14.3)
Location
Right colon 31 9 (29.0)
Left colon 63 24 (38.1)
*P < .0001.
Table 2. Characteristics of Study Population and Expression of miR-92a in Colorectal Cancer.
Colorectal Cancer n Expression of miR-92a↑ [Case (%)]
Sex
Male 25 16 (64.0)
Female 13 9 (69.2)
Age
<69 18 13 (72.2)
>70 20 12 (60.0)
Clinical stage
0 7 2 (28.6)*
I 10 6 (60.0)
II 8 8 (100.0)
IIIa 9 7 (77.8)
IIIb 1 1 (100.0)
IV 3 1 (33.3)
Depth
Mucosa (M) 7 2 (28.6)†
Submucosa (SM) 6 5 (83.3)
Mucosa propria (MP) 4 1 (25.0)
Subserosa (SS) 8 7 (87.5)
Serosa exposure, serosa invasion (SE, SI) 13 10 (76.9)
Tumor diameter (mm)
<40 19 16 (84.2)‡
>40 19 9 (47.4)
Dukes classification system
A 24 14 (58.3)
B 2 2 (100.0)
C 12 9 (75.0)
Location
Right colon 11 7 (63.6)
Left colon 27 18 (66.7)
*Clinical stage 0 versus I to IV; P = .022.
†Depth M versus SM-SI; P = .022.
‡P = .017.
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Dickinson, Franklin Lakes, NJ) and cultured in complete medium
(EGM BulletKit; Lonza, Walkersville, MD) under an atmosphere of
95% air and 5% CO2 at 37°C. Normal diploid fibroblast ASF-4-1 cells
were also seeded in six-well plates precoated with gelatin (BIOCOAT;
Becton Dickinson) and cultured in RPMI-1640 medium supple-
mented with 15% (vol/vol) heat-inactivated FBS under an atmosphere
of 95% air and 5% CO2 at 37°C. To collect cancer cell–derived MVs,
we also used MV-free RPMI medium supplemented with 10% FBS.
MV-free FBS was made and added into RPMI medium as follows:
FBS was centrifuged at 3000 rpm for 5 minutes and its supernatant
was filtered through a Millex-HV Filter Unit (0.45-μm pores; Merck
Millipore, Billerica, MA). The flow through was ultracentrifuged at
100,000 rpm for 3 hours. Without disturbing the MV pellet, the
supernatant was used as MV-free FBS. The number of viable cells
was determined by performing the trypan blue dye exclusion test.
Human Tumor Xenograft Model
Our institute’s committee for ethics in animal experimentation
approved all animal experimental protocols. Animal experiments were
conducted in accordance with the guidelines for Animal Experiments
of Gifu International Institute of Biotechnology. Thirteen athymic
nude mice were inoculated with human colon cancer DLD-1 cells
at 1 × 107 cells in 100 μl of phosphate-buffered saline (PBS) into
their subcutaneous flank, and the inoculation time was set as day 0.
Thirteen control mice received a PBS injection. All tumor volumes
were monitored by measuring the length (L), width (W ), and depth
(D), and volumes were estimated according to the following formula:
V (mm3) = L × W × D × 0.5. Blood sampling was carried out on
all animals from the abdominal aorta at week 8 after the inoculation
under general anesthesia with an intraperitoneal injection of 50 mg/kg
pentobarbital sodium (Somnopentyl; Kyoritsu Seiyaku Co, Tokyo,
Japan) and then sacrificed. Blood was stored at 4°C in 2-ml EDTA
tubes for further experiments. Blood processing was done within
2 hours after the sampling.
RNA Isolation from Circulating MVs in Mouse Blood
We isolated total RNAs contained within the MVs in the mouse
blood according to the protocol recommended in the ExoMir Kit
(Bioo Scientific Co, Austin, TX). Briefly, whole blood samples were
centrifuged at 6000g for 5 minutes to remove blood cells. The super-
natant plasma (400-500 μl) was then diluted with 5 ml of PBS and
filtered through a Millex-HV Filter Unit (0.45-μm pores; Merck
Millipore) to remove cell debris. The filtered samples were further
filtered through two filters (pore sizes of 0.22 and 0.02 μm) provided
in the ExoMir Kit. The MVs were captured by the 0.02-μm filter after
passage through the 0.22-μm filter. The total RNAs were extracted
from the trapped MVs and used for analysis.
Transfection with miR-92a, antagomiR-92a, or
Short-Interfering RNA for Dkk-3
DLD-1 cells, WiDr cells, and/or HUVECs were seeded in six-well
plates at a concentration of 0.5 × 105 per well (10-30% confluence) on
the day before the transfection. The mature type of miR-92a (mirVana
miRNA mimic; Ambion, Foster City, CA), antagomiR-92a (mirVana
miRNA inhibitor; Ambion), or short-interfering RNA (siRNA) for
Dkk-3 (siR–Dkk-3; Invitrogen, Carlsbad, CA) was used for the trans-
fection of the cells, which was achieved by using cationic liposomes,
Lipofectamine RNAiMAX (Invitrogen), according to the manufacturer’s
Lipofection protocol. The nonspecific control miRNA (HSS, Hokkaido,
Japan) sequence was 5′-GUAGGAGUAGUGAAAGGCC-3′, which
was used as a control for nonspecific effects [16]. The sequence of
themature type of miR-92a used in this study was 5′-GUCCAGUUU-
UCCCAGGAAUCCCUU-3′ and that of siR–Dkk-3 were 5′-GAUG-
AGUAUGAAGUUGGCAGCUUCA-3′ and 5′-CCCTCTTTGGCA-
GTTGCATTAGTAA-3′. The effects manifested by the introduction
of miR-92a into the cells were assessed at 72 hours after the transfection.
Quantitative Reverse Transcription–Polymerase Chain
Reaction Using Real-Time Polymerase Chain Reaction
Total RNA was isolated from cultured cells or tumor tissues by
using TRIzol containing phenol/guanidium isothiocyanate (Applied
Biosystems, Foster City, CA) and treatment with DNase I. RNA con-
centration and purity were assessed by UV spectrophotometry. RNA
integrity was checked by formaldehyde gel electrophoresis. For deter-
mination of the expression levels of mRNAs, total RNA was reverse-
transcribed with PrimeScript RT reagent Kit (TaKaRa, Otsu, Japan).
Quantitative reverse transcription–polymerase chain reaction (qRT-
PCR) was performed with primers specific for Dkk-3 by using SYBR
Premix Ex Taq (TaKaRa). The primers for Dkk-3 were given as
follows: Dkk-3–sense, 5′-TTC GGG TAG TGG AAA ACC AG-3′,
and Dkk-3–antisense, 5′-CAG CAG CTC GAA TTT CTT CC-3′.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH ) was used as an
internal control. All reactions were run in triplicate. The relative
expression levels of mRNAs were calculated by the ΔΔC t method.
To determine the expression levels of miRNAs, we conducted qRT-
PCR by using TaqMan MicroRNA Assays (Applied Biosystems)
according to the manufacturer’s protocol. In brief, RT reactions con-
tained 25 ng of total RNA samples, 50 nM stem-loop RT primer
(Applied Biosystems), and reagents from a TaqMan MicroRNA
Reverse Transcription Kit (Applied Biosystems). The RT reactions
were run in an ABI thermocycler for 30 minutes at 16°C, 30 minutes
at 42°C, 5 minutes at 85°C, and then held at 4°C for 10 minutes. Real-
time PCR was performed by using PCR primers (Applied Biosystems)
and Premix Ex Taq (TaKaRa). The 20-μl PCR reaction mixture
included 2.0 μl of RT product, 10 μl of Premix Ex Taq, and 1 μl of
PCR primer. These reaction mixtures were incubated at 95°C for
10 seconds, followed by 40 cycles of 95°C for 5 seconds, and 60°C
for 30 seconds. All reactions were run in triplicate. The relative expres-
sion levels of miR-92a were calculated by the ΔΔC t method. RNU6B
was used as an internal control.
Table 3. Characteristics of Study Population and Expression of miR-92a in Colorectal Adenoma.
Colorectal Adenoma n Expression of miR-92a↑ [Case (%)]
Sex
Male 31 7 (22.6)*
Female 25 1 (4.0)
Age
<59 30 5 (16.7)
>60 26 3 (11.5)
Tumor diameter (mm)
<10 28 5 (17.8)
>10 28 3 (10.7)
Grade
Low-grade dysplasia 41 5 (12.2)
High-grade dysplasia 15 3 (20.0)
Location
Right colon 20 2 (10.0)
Left colon 36 6 (16.7)
*P < .0001.
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Western Blot Analysis
Whole cells were homogenized in chilled lysis buffer comprising
10 mM Tris-HCl (pH 7.4), 1% NP-40, 0.1% deoxycholic acid,
0.1% sodium dodecyl sulfate, 150 mM NaCl, 1 mM EDTA, and
1% Protease Inhibitor Cocktail (Sigma-Aldrich Co) and stood for
20 minutes on ice. After centrifugation at 13,000 rpm for 20 minutes
at 4°C, the supernatants were collected as whole-cell protein samples.
Protein contents were measured with a DC Protein assay kit (Bio-Rad,
Hercules, CA). Ten micrograms of lysate protein was separated by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis using 12.5%
polyacrylamide gels and electroblotted onto a polyvinylidene difluoride
(PVDF) membrane (PerkinElmer Life Sciences, Inc, Boston, MA). After
blockage of nonspecific binding sites for 1 hour with 5% nonfat milk in
PBS containing 0.1% Tween 20 (TBS-T), the membrane was incubated
overnight at 4°C with antibodies against DKK-3 (Santa Cruz Bio-
technology, Santa Cruz, CA) properly diluted with TBS-T containing
2% BSA and 0.01% sodium azide. The membrane was then washed
three times with TBS-T, incubated further with HRP-conjugated goat
anti-rabbit IgG antibody (Cell Signaling Technology) at room tempera-
ture, and then washed three times with TBS-T. The immunoblots were
visualized by use of Amersham ECL Plus Western Blotting Detection
Reagents (GE Healthcare, Buckinghamshire, United Kingdom). The
quantity loaded was verified by re-incubating the same membrane with
anti–β-actin antibody (Sigma-Aldrich Co).
Luciferase Assay
DLD-1 or WiDr cells were seeded into 12-well plates at a con-
centration of 0.5 × 105 per well on the day before the transfection.
Searching the Target Scan 6.2 database (http://www.targetscan.org/)
to find algorithm-based binding sites of miR-92a, we found the
predicted binding sites to be at position 1317-1324 in the 3′UTR of
Dkk-3 mRNA. The sequence region 1081-1449 containing the puta-
tive binding sequence of miR-92a was inserted into a pMIR-REPORT
Luciferase miRNA Expression Reporter Vector (Applied Biosystems)
according to the manufacturer’s protocol. Moreover, we made another
pMIR construct encompassing a mutated seed sequence for miR-92a
(wild type, GTGCAAT; mutant, GTTACAT) by using a PrimeSTAR
Mutagenesis Basal Kit (TaKaRa). The mutation of the vector was
confirmed by sequence analysis. pRL-TK Renilla luciferase reporter
vector (Promega, Madison, WI) was used as an internal control vector.
DLD-1 or WiDr cells were co-transfected with each reporter vector
(0.1 μg/well each) and 20 nM miR-92a or nonspecific noncoding
siRNA (Dharmacon, Tokyo, Japan), which was achieved by using
Lipofectamine RNAiMAX. Luciferase activities were measured at
48 hours after co-transfection by using a Pikka-Gene Dual (TOYO
B-Net, Co, Ltd, Tokyo, Japan) according to the manufacturer’s pro-
tocol. Luciferase activities were reported as the firefly luciferase/Renilla
luciferase ratio.
Matrigel Invasion Assay
DLD-1 and WiDr cells for antagomiR-92a transfection were seeded
into six-well plates at a concentration of 0.5 × 105 per well and
transfected with antagomiR-92a. The cells were then trypsinized at
48 hours after the transfection, suspended at a concentration of
1.25 × 105 per ml in 2 ml of serum-free RPMI, and seeded into
8-μm porous BioCoat Matrigel chamber inserts (BD Biosciences,
San Jose, CA). The chamber inserts were placed in wells filled with
2.5 ml of RPMI supplemented with 10% FBS as chemoattractant.
After 22 hours of incubation, the upper side of the filter was scraped
with a cotton tip to eliminate cells that had not migrated through it.
The invasive ability of the cells was determined by counting the cells
stained with Wright-Gimsa that had migrated to the lower side of the
filter. The counting was done from photomicrographs.
Wound Healing Assay
HUVECs were seeded into 12-well plates at a concentration of
0.5 × 105 per well 2 days before the transfection. A straight line
scratch, which simulated a wound, was made by the tip of a sterile
pipette at 48 hours after transfection. The cells were then washed
with PBS and refreshed with serum-free medium to exclude the
effect of cell growth facilitated by serum. After overnight incubation
at 37°C, the cells were fixed in absolute methanol. The initial gap
length (0 hour) and the residual gap length (24 hours) after the
scratches had been made were calculated from photomicrographs.
Tube Formation Assay
Tube formation assay was conducted according to the manufac-
turer’s protocol of the Angiogenesis Starter Kit (Life Technologies,
Carlsbad, CA). HUVECs were seeded into six-well plates at a con-
centration of 0.5 × 105 per well on the day before the transfection.
Tube formation assay was performed at 24 hours after transfection.
Tracking Experiment of Nascent miR-92a Derived from
DLD-1 Cells into HUVECs Using MVs
Nascent miR-92a was traced according to the manufacturer’s pro-
tocol of the Click-iT Nascent RNA Capture Kit (Invitrogen). Briefly,
DLD-1 donor cells were incubated overnight in medium contain-
ing 0.2 mM 5-ethynyl uridine (EU, an alkyne-modified nucleotide),
which is efficiently and naturally incorporated into the nascent RNA.
After an overnight incubation, total RNA was extracted from the
donor cells. To purify MVs from the donor’s medium, we subjected
the medium sequentially to centrifugation at 2000 rpm for 10 min-
utes, filtration through a 0.45-μm filter, and ultracentrifugation at
100,000 rpm for 3 hours. The MV-concentrated solution was diluted
with 0.1 ml of PBS. This PBS solution containing MVs was added to
the medium of recipient HUVECs or ASF-4-1 cells. After overnight
incubation, total RNA was extracted from the recipient cells. As a
negative control, we used EU-free RNAs from donor cells, MVs, and
recipient cells. RNAs labeled with EU were extracted by using the
copper-catalyzed click reaction with azide-modified biotin, which
created a biotin-based handle for capturing nascent RNA transcripts
on streptavidin magnetic beads.
Statistics
Each examination was performed in triplicate. The expression
levels > 1.5 were designated as up-regulation and those <0.67 as
down-regulation, with fold changes obtained from the results of
linear discriminant analysis of miR-92a expression patterns from
38 pairs of colon tumors and nontumorous tissues. The tumor/
nontumor ratio of miR-92a expression in the samples was also
expressed by use of box-and-whisker plots. Statistical differences be-
tween clinicopathologic parameters and the miR-92a level of tumor
samples were evaluated by using the Pearson χ2 test or Fisher exact test
for comparison between two groups. All calculations were performed
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by using software JMP (version 5.1; SAS Inc, Cary, NC). In transfec-
tion experiments, differences were statistically evaluated by one-way
analysis of variance followed by Tukey method or the unpaired t test.
All calculations were conducted by using GraphPad Prism software
system (GraphPad Software, Inc, La Jolla, CA). A P value < .05 was
considered to be statistically significant.
Results
Plasma miR-92a/MVs Levels Were Significantly Increased
in Xenograft-Bearing Mice with DLD-1 Cells
The miR-92a level was recently reported to be increased in the
plasma from colon cancer patients [17]. We also confirmed in a
colon cancer xenograft model whether miR-92a/MVs could serve
as a circulating colon cancer marker by comparing its plasma level
between xenograft mice and control mice. A significant increase in
the plasma miR-92a/MVs level was observed in 10 of 13 mice
(76.9%) compared with the levels for the 13 control mice (Figure 1A).
The tumor-bearing mouse/control mouse ratios of miR-92a/MVs
expression in the plasma samples were also expressed as box-and-whisker
plots (Figure 1B).
Relationship between the Expression of miR-92a in
Colorectal Tumors and Clinicopathologic Findings
The clinicopathologic findings and frequencies of up-regulation
of miR-92a tested in a total of 94 patients with colorectal cancer
Figure 1. Expression levels of miR-92a/MVs in the plasma of DLD-1 cell xenograft-bearing mice. Ratios of the level of circulating
miR-92a/MVs in the plasma of 13 tumor-bearing mice to that of 13 control mice are shown as (A) column bars and (B) box-and-whiskers
plot. Data were expressed as the means ± SD. The P value was stated as follows: *P < .05, **P < .01, and ***P < .001.
Figure 2. Expression level of miR-92a examined by qRT-PCR. (A) miR-92a relative expression levels in various human normal tissues.
miR-92a expression levels were significantly lower (***P< .001) in colonmucosa tissues compared with those in other tissues. (B) miR-92a
relative expression levels in four human colon cancer cell lines and in corresponding normal colon tissue (***P < .001). The miR-92a
expression levels were normalized by using RNU6B as an internal control.
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(38 cases) or adenoma (56 cases) are shown in Tables 1 to 3. The ex-
pression level of miR-92a was significantly higher in the cancers than
in the adenomas (P < .0001; Table 1). Significant up-regulation of
miR-92 was observed in the smaller cancers (<40 mm; P = .017) and
in cancers classified as clinical stages I to IV compared with those in
stage 0 (P = .022; Table 2). Interestingly, the up-regulation of miR-92a
was associated with the invasiveness of the cancer cells. We previously
reported that good markers for discrimination between cancer and
Figure 3. Validation of Dkk-3 as a target gene of miR-92a in colon cancer cells. (A) Expression level of Dkk-3 mRNA in four colon cancer
cell lines. GAPDH was used as an internal control (***P < .001). (B) Predicted binding site for miR-92a in the 3′UTR region of human
Dkk-3 mRNA (region A shown as a red box). Mutant-type pMIR vector was inserted with mutated seed sequence (from GCA to TAC)
for miR-92a. (C) Luciferase activities after co-transfection with control or miR-92a and wild-type or mutant-type pMIR vectors having the
indicated 3′UTR of Dkk-3 (***P < .001). A P value was determined for the difference in luciferase activity between the cells transfected
with nonspecific control siRNA (Dharmacon) and those transfected with miR-92a.
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adenoma are miR-7, -21, and -34a, and that the down-regulation of
miR-143 and -145 is an overall marker of colon tumors [18]. As a
result of this present study,miR-92awas also shown to be a goodmarker
for discrimination between cancer and adenoma.
miR-92a Was Specifically Upregulated in
Colon Cancer Cell Lines
First, we examined the tissue distribution of miR-92a and found that
the expression level of miR-92a in colon tissue was extremely low
Figure 4. Effects of transfection of colon cancer cells with antagomiR-92a. (A) Cell viability and (B) DKK-3 protein expression levels at
72 hours after antagomiR-92a transfection at a concentration of 40 or 60 nM in DLD-1 cells and 20 or 40 nM in WiDr cells (*P < .05,
**P < .01, and ***P < .001). β-actin was used as an internal control, and densitometric values were calculated for DKK-3. (C) Cell
invasion evaluated in the Matrigel invasion assay (*P < .05 and **P < .01). Representative microscopic images are presented in the
upper panel of each assay graph.
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compared with that in the other tissues tested (Figure 2A). The relative
expression level of miR-92a was significantly increased in colon cancer
cell lines, DLD-1, COLO201, SW480, and WiDr cells compared with
that in normal colon mucosal tissue (Figure 2B). These data suggest
that miR-92a had a specific oncogenic function in colon cancer cells.
miR-92a Targeted the 3′UTR Sequence of Dkk-3 in
Colon Cancer Cells
To validate the role of up-regulation and secretion of miR-92a
in colon cancers, we examined the effect of it on a potential target
gene, Dkk-3. Dkk-3 had previously been shown to be a target gene
of miR-92a in neuroblastomas [19]. The biologic role of DKK-3 in
colon cancer still remains unclear; however, several reports have
shown DKK-3 to have a tumor-suppressive function [20–22].
In this study, the expression level of the Dkk-3 gene in the four
colon cancer cell lines examined was markedly downregulated com-
pared with that in normal colon tissue (Figure 3A). The predicted
binding site for miR-92a in the 3′UTR region of human Dkk-3
mRNA was confirmed on the basis of the database (TargetScan;
http://targetscan.org/) and cloned into the downstream of the firefly
luciferase gene in the pMIR-REPORT vector (Figure 3B). As ex-
pected, compared with those of the control, the luciferase activity of
the wild-type pMIR–Dkk-3 region A was significantly inhibited after
the introduction of miR-92a into the DLD-1 cells (data not shown)
and WiDr cells (Figure 3C ). Mutation of the Dkk-3 3′UTR-binding
site in region A abolished the ability of miR-92a to regulate luciferase
expression (Figure 3C). These results also demonstrated Dkk-3 to be
a potential target of miR-92a in colon cancer.
antagomiR-92a Transfection Inhibited Cell Growth and
Cell Invasion and Restored DKK-3 Expression in
Colon Cancer Cells
Our results suggested that up-regulation of miR-92a in colon cancer
cells contributed to the regulation of DKK-3 expression. Next, we
antagonized miR-92a to confirm the role of miR-92a on Dkk-3 in
colon cancer cells. As expected, transfection of DLD-1 or WiDr cells
with the antagomiR-92a resulted in a significant growth inhibition and
restored DKK-3 expression levels (Figure 4, A and B). The expression
level of DKK3 and the growth inhibition at 60 nM antagomir-92a
in DLD-1 cells were not dose dependent, which would indicate an
off-target effect. Moreover, cancer cell invasion was also significantly
reduced by antagomiR-92a in the Matrigel invasion assay (Figure 4C).
Nascent miR-92a from Colon Cancer Cells Was Transferred to
Endothelial Cells through MVs Traced by Using EU
To validate the role of miR-92a secretion by colon cancer cells
through MVs, we traced EU-labeled miR-92a from donor DLD-1 cells
to recipient HUVECs or ASF-4-1 cells. As shown in Figure 5A, the
Figure 5. Evidences of miR-92a transfer from donor DLD-1 cells to recipient HUVECs or ASF-4-1 cells. (A) Relative expression levels of EU-
labeledmiR-92a traced from donor cell (DLD-1)–derivedMVs to recipient cells (HUVECs or ASF-4-1). Nascent RNU6B was used as an internal
control. Expression levels of EU-free miR-92a and RNU6B were used as normalizers. (B) Relative expression levels of endogenous miR-92a in
DLD-1, HUVECs, and ASF-4-1 cells and intracellular level of miR-92a in recipient cells following incubation with MVs (*P < .05). Expression
level of RNU6Bwasused as internal control. (C) Cell viability of HUVECsandASF-4-1 cells following incubationwithMVs. HUVECs andASF-4-1
cells were seeded at 0.2 × 105/well in 24-well plate, and the percentage of viable cells was determined at 48 hours after exposure to DLD-1–
derived MVs (*P < .05, and **P < .01). These MVs were collected from 2 × 107 DLD-1 cells incubated for 3 days in MV-free medium.
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donor cell’s intracellular EU-labeled miR-92a moved into MVs. EU-
labeled miR-92a/MVs was then transferred into the recipient HUVECs
and detected within the cells; however, EU-labeled miR-92a/MVs
within the recipient ASF-4-1 cells was barely detected (C t value > 39;
Figure 5A). Furthermore, following incubation with MVs, significant
increase in the intracellular level of miR-92a was observed in HUVECs
compared with its endogenous level of miR-92a but not in ASF-4-1 cells
(Figure 5B). These results suggested that miR-92a released into the
bloodstream from colon cancer cells could tend to be transferred to the
endothelial cells through MVs. However, we observed a significant
growth promotion not only in HUVECs but also in ASF-4-1 cells by
treatment of them with DLD-1–derived MVs (Figure 5C).
Figure 6. Effects of transfection of HUVECs with miR-92a or siR–Dkk-3 on their proliferation, motility, and tube formation. (A) Cell viability
and relative expression of DKK-3mRNA and protein at 72 hours after the transfection with nonspecific control miRNA, miR-92a, or siRNA
for Dkk-3 (siR–Dkk-3) at 10 nM (**P < .01 and ***P < .001). (B) Cell motility evaluated by use of the wound healing assay. The wound
(scratch) was made at 24 hours after the transfection with nonspecific control miRNA, miR-92a, or siR–Dkk-3 at 10 nM (pre; 0 hour). The
percentage of remaining wound area was determined at 24 hours after the scratch (post; 24 hours). The cell migration activity is shown
as a decrease in the percentage of the wound area remaining compared with that of the wound area at 0 hour (***P < .001; scale bar,
200 μm). (C) Tube formation activity was observed by use of the tube formation assay. HUVECs were moved into the 24-well plate for
tube formation assay at 24 hours after the transfection with nonspecific control miRNA, miR-92a, or siR–Dkk-3 at 10 nM. Because of
increased number of viable cells, firm and well-netted structures were constructed in miR-92a or siR–Dkk-3–transfected cells compared
with that of nonspecific control. Bar, 200 μm.
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miR-92a, Acting as a Suppressor of DKK-3, Increased Cell
Growth and Cell Motility in HUVECs
As we showed that miR-92a secreted from colon cancer cells was de-
livered to the endothelial cells through MVs, we transfected HUVECs
with mature miR-92a to validate the role of miR-92a in the endothelial
cells. As expected, the cell growth was significantly enhanced, and
DKK-3 expression was significantly downregulated at both mRNA
and protein levels (Figure 6A). Gene silencing of Dkk-3 (siR–Dkk-3)
also increased cell growth through the down-regulation of DKK-3
(Figure 6A). HUVEC motility and tube formation were also signifi-
cantly increased by miR-92a or siR–Dkk-3 transfection, as confirmed
by the results from the wound healing assay (Figure 6B) and tube
formation assay (Figure 6C ). These results suggested that the colon
cancer cells secreted miR-92a to elicit a suitable tumor environment
for angiogenesis through the down-regulation of Dkk-3.
Discussion
In this study, we showed that the level of circulating plasma miR-92a
was significantly increased even in mice bearing human colon cancer
xenografts. These findings support the possible use of miR-92a/MVs
as a novel biomarker for the early detection of colon cancer. To clarify
the contribution of miR-92a to colon cancer development and the
secretion of this miRNA through MVs, we examined the expression
level of miR-92a and its target gene in 94 clinical samples of colorectal
cancers and adenomas as well as in various colon cancer cell lines.
We further approached the significance of MVs for the transfer of
miR-92a from colon cancer cells to other cells by using HUVECs
and ASF-4-1 cells.
A significant increase in miR-92a expression was more frequently
observed in colorectal cancers than in colorectal adenomas, which
suggests that miR-92a could be a potential marker for discrimination
between cancers and adenomas and a potential promoter for the
phenotypic changes from adenoma into carcinoma. We also inves-
tigated the association of miR-92a expression with clinicopathologic
features. In the colorectal cancer group, we found that miR-92a
expression was related to advanced clinical stages and to the depth of
invasion. Interestingly, the increased expression of miR-92a was fre-
quently observed in the cancers smaller than 40 mm in diameter. In
the adenoma group, male patients had frequently increased miR-92a
expression in their tumors compared with that in those of female
patients. As to the relationship between the clinicopathologic charac-
teristics and miR-92a expression, Zhou et al. previously reported that
overexpression of miR-92a is correlated with tumor size, node status,
and metastasis classification (TNM) stage, lymph node and distant
metastasis, and poor prognosis in colorectal cancer [23]. Our data sup-
port their results and add some new findings to them. The precise
mechanisms behind the up-regulation of miR-92a in colorectal cancer
still remain unclear. Previous studies on neuroblastoma demonstrated
that c-Myc induces expression of the miR-17-92 cluster and that
two members of this cluster, miR-19b and miR-92a, regulate Dkk-3
expression post-transcriptionally [19,24,25]. In this present study, we
demonstrated that the up-regulation of miR-92a was rather a specific
phenomenon of colon cancer cells and that the target gene was the same
Dkk-3 in human colon cancer DLD-1 and WiDr cells. Moreover,
cancer cell growth and invasion were significantly inhibited when
miR-92a was antagonized and DKK-3 expression was restored. DKK-3
is a member of the DKK family of secreted Wnt antagonists. The func-
tions of other members of this family have been well elucidated; how-
ever, the role of DKK-3 still remains controversial. Reduced or silenced
Dkk-3 expression has been reported in several cancers including colon
cancer [21,26,27]. Recently, it was reported that overexpression of
Dkk-3 in cancer cells inhibits their motility and proliferation and in-
duces apoptosis [20,28]. Thus, accumulating evidence suggests that
Dkk-3 acts as an anti-oncogene and has functions beyond being merely
a canonical Wnt inhibitor. Our data support these studies.
miR-92a secreted by DLD-1 cells through MVs was delivered to
HUVECs and acted as a stimulant for cell growth, motility, and
tube formation through targeting Dkk-3, the same target gene in
colon cancer cells. The method used for the collection of MVs from
the plasma and culture medium was established in our laboratory.
MVs are a heterogeneous population of membrane-enclosed vesicles
released by eukaryotic cells through direct cargo export mecha-
nisms across the plasma membrane and not through signal peptide–
dependent secretory transport pathways [29]. Much remains to be
elucidated about the mechanisms by which MVs are formed and
shed at the cell surface; however, the roles of MVs in the tumor micro-
environment are being increasingly understood. One such role is the
positive impact of tumor-derived MVs on endothelial cells and angio-
genesis, which is needed for tumor survival and growth. Sphingomyelin,
a major component of the MVmembrane, contributes to the increased
motility and proliferation of endothelial cells [30]. Matrix metallo-
proteinases and vascular endothelial growth factor, crucial molecules
for vascularization, were shown to be packed within cancer-derived
MVs and to contribute to the enhanced motility of endothelial cells
[31,32]. In this study, miR-92a/MVs was barely detected in fibroblast
ASF-4-1 cells, although increased cell proliferation was observed follow-
ing incubation with MVs. It was suggested that besides miR-92a/MVs,
other contents of MVs and/or components of MV membrane like
sphingomyelin could also have contributed to the recipient cell prolif-
eration [30]. It seemed that HUVECs willingly uptake miR-92a/MVs
compared with ASF-4-1 cells; however, the recipient selection by
MVs and/or MV selection by recipient cells still remained unclear.
Our data suggest that colon cancer cells upregulated intracellular
miR-92a to downregulate the anti-oncogene Dkk-3 and also secreted
miR-92a–containing MVs into their surrounding environment to
facilitate angiogenesis. This process supplies more blood for the
increased demand for nutrients and oxygen for further growth of
the tumor. Further study will be needed to disclose the role of
DKK-3 in colorectal cancer and also in HUVECs and the mecha-
nisms involving secretion and selection of the MV’s components.
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